MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to free myelofibrosis patients from frequent blood transfusions
Disease control Recruiting nowThis study tests whether combining two drugs, momelotinib and luspatercept, can help people with myelofibrosis go without blood transfusions for at least 12 weeks. About 68 adults who either haven't tried or have already used certain other treatments will take part. The goal is t…
Matched conditions: MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC